Heme oxygenase-1 and hemopexin gene polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity in China.
Wenpei LiuLihuan LuHongqiu PanXiaomin HeMeiling ZhangNannan WangJia ZhuHonggang YiShao-Wen TangPublished in: Pharmacogenomics (2022)
Objective: To assess whether the risk of anti-tuberculosis drug-induced hepatotoxicity (ATDH) might be influenced by heme oxygenase-1 ( HMOX1 ) and hemopexin ( HPX ) gene polymorphisms. Methods: A dynamic anti-tuberculosis treatment cohort was constructed, and the 1:4 matched nested case-control study was analysed. Eight single-nucleotide polymorphisms (SNPs) of the two genes were selected for genotyping and Bonferroni correction was performed to correct for multiple comparison. Results: Overall, 7.8% of patients developed ATDH. SNP rs1807714 in the HMOX1 gene had decreased effects on the risk of moderate and severe hepatotoxicity under the dominant and additive models, and hepatocellular injury under the additive model. SNP rs2682099 in the HPX gene had increased effects on the risk of moderate and severe hepatotoxicity under the recessive model. However, these associations disappeared after Bonferroni correction. Conclusion: HMOX1 and HPX gene polymorphisms might not be associated with susceptibility to ATDH in the Chinese population.
Keyphrases
- drug induced
- genome wide
- liver injury
- adverse drug
- dna methylation
- mycobacterium tuberculosis
- copy number
- end stage renal disease
- ejection fraction
- hiv aids
- pulmonary tuberculosis
- newly diagnosed
- genome wide identification
- high intensity
- chronic kidney disease
- prognostic factors
- gene expression
- intellectual disability
- genetic diversity
- patient reported outcomes
- high density
- human immunodeficiency virus
- combination therapy
- replacement therapy